Sequence Listings in EPO Opposition Proceedings: Key Legal Considerations
Introduction In European patent practice, sequence listings play a critical role in biotechnology, pharmaceutical and genetic engineering patents. These listings – typically comprising nucleotide and amino acid sequences – are essential for disclosing biological inventions with precision and reproducibility. However, their importance becomes even more pronounced during opposition proceedings before the European Patent Office (EPO), […]
Cell Line Patents and Sequence Listings: What Biopharmaceutical Companies Need to Know
Introduction Cell line technologies have become a cornerstone of modern biopharmaceutical innovation. From monoclonal antibody production and gene therapies to vaccine development and regenerative medicine, proprietary cell lines often represent some of the most valuable intellectual property assets within a biotechnology company’s portfolio. However, securing patent protection for cell lines involves unique legal, technical, and […]
Managing Sequence Listings Across a Biotech Patent Portfolio: Best Practices
Introduction In the biotechnology industry, patents are often built around biological sequences that define the core of an invention. Whether the innovation relates to therapeutic proteins, monoclonal antibodies, gene-editing technologies, vaccines, diagnostic biomarkers, or nucleic acid constructs, sequence data frequently forms the foundation of patent protection. Consequently, sequence listings are not merely administrative filing documents; […]
AI-Assisted Sequence Listing Preparation: Opportunities and Compliance Risks
Introduction Biotechnology and pharmaceutical patenting increasingly rely on sequence listings to describe nucleic acid and amino acid sequences in a standardized, machine-readable format. As patent filings grow more complex and data-heavy, artificial intelligence (AI) tools are being adopted to assist in generating, validating and formatting sequence listings. However, while AI introduces significant efficiency gains, it […]
Sequence Listing Requirements in Patent Reissue and Reexamination Proceedings
Introduction In biotechnology and pharmaceutical patent law, sequence listings occupy a uniquely technical and legally determinative role. Unlike ordinary textual disclosures in patent specifications, sequence listings translate biological innovation into structured, machine-readable data that defines the boundaries of genetic and protein-based inventions. These listings are not peripheral attachments; they frequently form the core identity of […]
Phage Display Patent Applications: Sequence Listing Requirements and Challenges
Introduction Phage display technology has become one of the most influential platforms in modern biotechnology for discovering and optimizing peptides, antibodies, and protein-protein interaction modulators. From therapeutic monoclonal antibodies to diagnostic binders and enzyme inhibitors, phage display-derived molecules appear frequently in patent filings across pharmaceuticals, diagnostics, and synthetic biology. However, despite its experimental flexibility, phage […]
Glycoprotein and Antibody-Drug Conjugate Sequence Listings in Patent Applications
Introduction The rapid evolution of biotechnology has transformed the pharmaceutical landscape, with glycoproteins and antibody-drug conjugates (ADCs) emerging as some of the most valuable and innovative therapeutic modalities. From monoclonal antibodies used in oncology and autoimmune disorders to sophisticated ADCs that selectively deliver cytotoxic payloads to cancer cells, these biologics represent a significant portion of […]
Non-Standard Amino Acids in Patent Sequence Listings: Encoding and Disclosure Rule
Introduction Biotechnology and pharmaceutical innovation increasingly extends beyond the twenty naturally occurring amino acids that form the foundation of most proteins. Advances in peptide engineering, synthetic biology, protein therapeutics, antibody development and biomolecular design have led to the widespread use of non-standard amino acids (NSAAs) to enhance stability, bioavailability, target specificity and therapeutic performance.As these […]
Modified Nucleotides in Sequence Listings: ST.26 Compliance for Non-Standard Bases
Introduction Modern biotechnology has outgrown the simplicity of the four-letter genetic alphabet. Today’s nucleotide sequences often include chemically modified bases engineered to improve stability, reduce immune response, or enhance binding efficiency. These innovations are not theoretical—they are the backbone of real-world therapeutics such as mRNA vaccines, antisense oligonucleotides, and gene-editing systems. But as molecular design […]
Aptamer Sequence Listings in Patent Applications: Disclosure, Compliance and Global Strategy Guide
Prelude Aptamers represent one of the most refined intersections of molecular biology and modern intellectual property law. These short, single-stranded DNA or RNA molecules are capable of folding into highly specific three-dimensional structures that bind to target molecules with antibody-like precision. Their applications span diagnostics, therapeutics, biosensing, drug delivery, imaging and precision medicine. Yet, despite […]